Compare Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Tax Managed Fund FTSE Developed Markets ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.16 (market cap $323.80B), while State Street SPDR S&P Biotech ETF trades at $153.21 (market cap $10.11B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 32× State Street SPDR S&P Biotech ETF's market cap, and Vanguard Tax Managed Fund FTSE Developed Markets ETF is more actively traded (17,001,112 versus 12,903,266). Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| VEA | XBI | |
|---|---|---|
Market Cap | $323.80B | $10.11B |
Volume | 17,001,112 | 12,903,266 |
52-Week High | $73.79 | $169.55 |
52-Week Low | $58.90 | $104.99 |
Typical Hold Time | 131 Days | 37 Days |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VEA trades at $70.19, down 0.1% with a bearish technical signal. The ETF shows mixed institutional activity with some firms increasing positions while others reduced holdings. Recent news highlights VEA's competitive advantages including a low 0.03% expense ratio and higher dividend yield compared to peers. Technical indicators show oversold conditions with RSI at 28.4, suggesting potential for near-term bounce.
The outlook remains cautious given bearish technical momentum, though the fund's cost efficiency and developed market exposure provide long-term value. Key risks include global market volatility and currency fluctuations. Investors should monitor institutional flow trends and global economic developments for directional cues.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
